| Dr Bryant Mark Whiting, MD | |
|
1380 E Medical Center Dr, Ste 2100, St George, UT 84790-2123 | |
| (435) 251-3250 | |
| (435) 251-3251 |
| Full Name | Dr Bryant Mark Whiting |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 17 Years |
| Location | 1380 E Medical Center Dr, St George, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760687388 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | TRN10997 (Florida) | Secondary |
| 208800000X | Urology | 8217924-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dixie Regional Medical Center | St george, UT | Hospital |
| Cedar City Hospital | Cedar city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.
George Washington University researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection.
You don't think you're hungry, then a friend mentions how hungry he is or you smell some freshly baked pizza and whoaaa, you suddenly feel really hungry. Or, you've had surgery and need a bit of morphine for pain. As soon as you hit that button you feel relief even though the medicine hasn't even hit your bloodstream.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.
George Washington University researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection.
You don't think you're hungry, then a friend mentions how hungry he is or you smell some freshly baked pizza and whoaaa, you suddenly feel really hungry. Or, you've had surgery and need a bit of morphine for pain. As soon as you hit that button you feel relief even though the medicine hasn't even hit your bloodstream.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bryant Mark Whiting, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: () - | Dr Bryant Mark Whiting, MD 1380 E Medical Center Dr, Ste 2100, St George, UT 84790-2123 Ph: (435) 251-3250 |
News Archive
Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.
George Washington University researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection.
You don't think you're hungry, then a friend mentions how hungry he is or you smell some freshly baked pizza and whoaaa, you suddenly feel really hungry. Or, you've had surgery and need a bit of morphine for pain. As soon as you hit that button you feel relief even though the medicine hasn't even hit your bloodstream.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
› Verified 4 days ago
Dr. J. Bryan Ellsworth, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 736 S 900 E Ste 108, St George, UT 84790 Phone: 435-628-3606 Fax: 435-628-8404 | |
Thomas S Brinton, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr Ste 2100, St George, UT 84790 Phone: 435-251-3250 | |
Robert Merrill Cope, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1490 E Foremaster Dr, Suite 300, St George, UT 84790 Phone: 435-688-2104 Fax: 435-628-5308 |